DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for pituitary gland disease — screening already-approved drugs against its 29-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePituitary gland disease maps to a 29-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pituitary gland disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase receptor type D (PTPRD) — PTPRD is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet flcdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2YD6 · 1.35 Å · ligand CITRATE ANION (FLC). Experimental structure, not a prediction.
What the evidence adds up to
The 2008 update on pituitary disease notes that thousands of papers were published that year, with selected highlights including advances in subcellular mechanisms of pituitary tumours and pituitary failure, new challenges with dopamine agonists for prolactinomas, and long-term prospective data on medical treatment for acromegaly. The review states these publications transformed understanding of normal and abnormal pituitary function and opened new research directions, but it provides no patient numbers, response rates, or survival data.
A 2011 review of aggressive pituitary tumours defines them by massive invasion and rapid growth, with poor prognosis because therapeutic options are limited and tumours are generally unresponsive to therapy. Surgery is first-line except for prolactinomas, but most aggressive tumours require repeated surgery. Dopamine agonists normalise prolactin in most prolactinoma patients, even those with macroprolactinomas, and somatostatin analogues can control re-expansion of pituitary adenomas, but both drug classes are less effective for aggressive adenomas than for non-aggressive ones. Radiotherapy is a third-line strategy when surgery and pharmacotherapy fail. Conventional chemotherapy is poorly effective, though recent case reports with temozolomide gave better short-term results. The review concludes that aggressive pituitary tumours recur quickly, are difficult to manage, and that early application of current approaches plus new developments is mandatory.
A 2018 review of new drug therapies for Cushing’s disease describes it as a rare systemic disease from ACTH oversecretion causing excess cortisol. Available pharmaceutical options exist but there is an unmet need for more effective treatment. Compounds targeting pituitary cell signalling or cell cycle control are listed: heat shock protein inhibitors (e.g. silibinin), histone deacetylase inhibitors (trichostatin A, vorinostat), kinase inhibitors (gefitinib, seliciclib), and others (triptolide, AT-101). Levoketoconazole and osilodrostat are in clinical testing and inhibit steroidogenesis. Blockade of ACTH receptor binding at the adrenal level is a theoretical target, and glucocorticoid receptor inhibition in peripheral tissue plays a minor role due to lack of biomonitoring options. The review states that further research and drug development of pituitary-directed targets are necessary, and that combination therapies may allow smaller doses but more data are needed.
A 2015 volume on GnRH receptors in pituitary tumour pathogenesis provides updates on functional anatomy, hypothalamic hormone receptors, transcription factors, growth factors, and signalling proteins, as well as transgenic models and chromosomal deletions in hereditary and sporadic adenomas. It offers no clinical trial results, no drug efficacy data, and no patient outcomes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Clinical Endocrinology & Metabolism · 2008 · 70 citations · open access
Update in Pituitary Disease
AbstractThe pituitary gland secretes vital trophic hormones that maintain homeostatic regulation of the metabolic milieu. Not surprisingly, several thousand papers relevant to the pituitary gland were published this past year, including publication of important transforming advances in our understanding of the pathogenesis, diagnosis, and treatment of pituitary disorders. In an attempt to focus on outstanding key articles reporting highlights of the year, quality inclusion criteria were applied. High-quality articles were selected for their translational impact, scientific advances, enrichment of new knowledge, influence on how we understand pituitary disorders, transformation of therapeutic principles, and opening up new research vistas. Using these selection criteria, highlighted papers within the following categorical topics were further selected for analysis and review: advances in understanding subcellular mechanisms subserving the pathogenesis of pituitary disorders including pituitary tumors and pituitary failure; new challenges facing the physician treating patients harboring prolactinomas with dopamine agonists; and the appearance of new publications reporting the efficacy of long-term prospective medical treatment of acromegaly that now provide more rigorous patient outcome information. Selected papers categorized by these topics all serve to significantly impact how the endocrinologist views disease pathogenesis, diagnosis, and treatment outcomes of patients with pituitary disease in 2007. The results of these publications have transformed our understanding of important principles underlying normal and abnormal pituitary function, as well as our approach to the management of pituitary disorders. Notably, they open up new vistas for creative scholarship in unraveling the challenges of pituitary medicine.
Expert Opinion on Pharmacotherapy · 2011 · 65 citations
Therapy of aggressive pituitary tumors
AbstractINTRODUCTION: Aggressive tumors of the pituitary gland are classically defined as pituitary tumors with a massive invasion of the surrounding anatomical structures and rapid growth. They are notoriously difficult to manage and are associated with poor prognosis because the therapeutic options are limited and the tumors are generally unresponsive to therapy. AREAS COVERED: This review focuses on treatment options for aggressive pituitary tumors, including surgery, radiotherapy and medical treatment, as well as focusing on the promising therapeutic options for aggressive pituitary tumors, evaluating the literature of the last 15 years. With the exception of prolactinomas, surgery is the first-line option, but most aggressive pituitary tumors often require repeated surgery. Pharmacotherapies are useful when surgery is unlikely to improve symptoms, or as an adjunct therapy to surgery. In prolactinomas, dopamine agonists are the first-line treatment and normalize prolactin levels in most patients, even those with macroprolactinomas. Somatostatin analogs are effective agents for primary therapy, pre-operatively or post-operatively to control tumor re-expansion of pituitary adenomas. However, dopamine agonists and somatostatin analogs are not as effective as they are for the treatment of non-aggressive adenomas. When surgery and pharmacotherapy fail, radiotherapy is a useful third-line strategy. Conventional chemotherapy is poorly effective but recent case reports with the temozolomide, an alkylating agent, have provided better results in the short term. EXPERT OPINION: Aggressive pituitary tumors are associated with poor prognosis as therapeutic options are limited. Moreover, they tend to recur quickly after initial treatment, are generally unresponsive to therapy, and are difficult to manage. To improve the overall response rate, the early application of current therapeutic approaches with the incorporation of new therapeutic developments is mandatory.
Expert Opinion on Pharmacotherapy · 2018 · 15 citations
New and emerging drug therapies for Cushing’s disease
AbstractINTRODUCTION: Cushing's disease is a rare systemic and disabling disease due to oversecretion of adrenocorticotrophic hormone (ACTH) resulting in excess cortisol levels. Diagnosis and treatment are difficult; despite the availability of various pharmaceutical treatment options, there is an ongoing, unmet need for even more effective treatment. AREAS COVERED: The present review aims at providing an overview of available drugs and presenting new developments. Focusing on the pituitary as a target, the review covers compounds targeting pituitary cell signaling or cell cycle control such as heat shock protein inhibitors (e.g. silibinin), histone deacetylase inhibitors (trichostatin A, vorinostat), kinase inhibitors (gefitinib, seliciclib), and others (such as triptolide, AT-101). Levoketoconazole and osilodrostat are in clinical testing and inhibit steroidogenesis. Blockade of ACTH receptor binding at the adrenal level is explained as a theoretical drug target. Inhibition of binding of the glucocorticoid receptor in the peripheral tissue plays a minor role due to its lack of biomonitoring options. EXPERT OPINION: In our opinion, further research and drug development of pituitary-directed targets are necessary. Combination therapies may exert synergistic effects and allow for smaller and better tolerated doses, but more experience and data are needed to guide such treatment schemes.
Journal of Internal Medicine and Emergency Research · 2024 · 1 citations · open access
A Review of Pituitary Gland for General Physicians
AbstractAbnormalities of the pituitary gland are common; general physicians should be confident in managing pituitary gland disorders like panhypopituitarism which is deficiency of hormones secreted by the pituitary gland and can be life threatening, hypersecretion of pituitary hormones which can lead to multiple comorbidities, and diagnosing pituitary adenomas which may have mass effect and serious consequences. This publication is a general approach to anatomy, physiology, and pathology of pituitary gland to aid diagnosis and management of common presentations related to pituitary gland disorders through literature review.
Frontiers of hormone research · 2015 · 0 citations
Role of GnRH Receptors in the Pathogenesis of Pituitary Tumors1
AbstractThis comprehensive volume focuses on mechanisms leading to pituitary tumor formation and progression. The individual chapters provide timely updates on developments in the rapidly expanding field of pituitary tumor pathogenesis. Researchers from leading centers describe the fundamental functional anatomy of the pituitary, the structure and function of the hypothalamic hormone receptors as they relate to human pituitary adenomas, as well as disordered transcription factors, growth factors and signaling proteins in pituitary tumorigenesis. They also present transgenic models of pituitary tumor formation and report on chromosomal deletions observed in both hereditary and sporadic adenomas. The book is an essential and timely resource for basic and clinical endocrinologists, neurosurgeons and neuro-oncologists as it provides a state-of-the-art summary of our current understanding of the pathogenesis of these common tumors.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
